Aurobindo Pharma shares rose 6.05 per cent to close the day at Rs 156.05, on completion of a licensing and supply agreement with Pfizer for supply of finished dosage products. Aurobindo has sold marketing rights for 39 generic solid oral dose products for the US and 20 for Europe.
These medicines cover the therapeutic areas, including cardiovascular disease and central nervous system disorders. The stock made an intraday high of Rs 163.45 and a low of Rs 144.05 with trading volumes of 1.67 lakh shares (around 4-times higher than its two-week average).
